Effects of different does intravitreous triamcinolone acetonide for macular edema secondary to retinal vein occlusion

AIM: To compare the clinical efficacy and complications of intravitreal injection of 1mg, 2mg and 4mg triamcinolone acetonide(TA)in the treatment of macular edema secondary to retinal vein occlusion, and to explore effective and safe injection dose. METHODS: Totally 62 patients(62 eyes)with venous obstructive macular edema were divided into 1mg intravitreal injection of TA(IVTA)group, 2mg IVTA group and 4mg IVTA group, including 18 cases in group 1mg, 22 cases in 2mg group, and 22 cases in 4mg group according to the dosage of intravitreous. The intravitreal injection of TA as the dosage of 1mg/0.025mL, 2mg /0.05mL, 4mg/0.1mL were taken. At 1, 3 and 6mo after the injection, the items including best corrected visual acuity(BCVA), central macular thickness center(CMT), intraocular pressure and complications were examined and compared between the three groups. RESULTS: There was no significant difference in age, sex, course of disease, BCVA, CMT and intraocular pressure in the three groups before injection(P>0.05). In 1mg IVTA group, BCVA and CMT were improved 1 and 3mo after treatment, compared with those before treatment(PPP>0.05), which was better than that of 1mg IVTA group(PCONCLUSION: The 2mg triamcinolone acetonide may be a suitable dose of intravitreous intravitreal injection for the treatment of macular edema secondary to retinal vein occlusion